Metraipolis › archive › dc_71600b23c993

Network Pharmacology and Molecular Docking-Based Investigation of Empagliflozin's Therapeutic Potential in Chronic Kidney Disease — Europe PMC PMID:42195274

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42195274
DOI
10.3390/life16050719
License (as archived)
solo-consultazione
Archived
2026-11-03T06:39:28.130Z
SHA-256 of the archived text
1d50d3f86a64424c43a7b2725bc36d621725b7e2f6d997e0c41db3b1614cc3d2
Stable URL of this page
https://metraipolis.com/documento/dc_71600b23c993

How to cite

Network Pharmacology and Molecular Docking-Based Investigation of Empagliflozin's Therapeutic Potential in Chronic Kidney Disease — Europe PMC PMID:42195274 — Europe PMC (en), https://europepmc.org/article/MED/42195274 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_71600b23c993 (Metraipolis archive dc_71600b23c993, sha256 1d50d3f86a64424c43a7b2725bc36d621725b7e2f6d997e0c41db3b1614cc3d2)
BibTeX
@misc{dc71600b23c993,
  title = {Network Pharmacology and Molecular Docking-Based Investigation of Empagliflozin's Therapeutic Potential in Chronic Kidney Disease — Europe PMC PMID:42195274},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42195274},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_71600b23c993; sha256 1d50d3f86a64424c43a7b2725bc36d621725b7e2f6d997e0c41db3b1614cc3d2},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42195274. Agents can read the archived copy with the MCP tool read_document.